Repligen Corporation (RGEN)
Repligen (RGEN) Down 3.2% Since Last Earnings Report: Can It Rebound?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Repligen Has A Cleaner Recovery Angle, But With High Valuation
Repligen Has A Cleaner Recovery Angle, But With High Valuation
Repligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Repligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Repligen's Q1 Earnings & Revenues Beat Estimates, Stock Rises
RGEN tops Q1 earnings and revenue estimates, sending shares higher as strong chromatography and analytics business aid growth. The company raises its 2026 EPS view.
Repligen Corporation (RGEN) Q1 2026 Earnings Call Transcript
Repligen Corporation (RGEN) Q1 2026 Earnings Call Transcript
Repligen (RGEN) Q1 Earnings and Revenues Beat Estimates
Repligen (RGEN) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.39 per share a year ago.
Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen (RGEN) Down 13.5% Since Last Earnings Report: Can It Rebound?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Repligen Corporation (RGEN) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript
Repligen Corporation (RGEN) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript
Cinctive Capital Management LP Takes Position in Repligen Corporation $RGEN
Cinctive Capital Management LP bought a new stake in shares of Repligen Corporation (NASDAQ: RGEN) during the undefined quarter, according to its most recent filing with the SEC. The firm bought 25,420 shares of the biotechnology company's stock, valued at approximately $3,398,000. Other hedge funds and other institutional investors have also recently bought
Repligen Corporation (NASDAQ:RGEN) Receives Consensus Rating of “Moderate Buy” from Brokerages
Shares of Repligen Corporation (NASDAQ: RGEN - Get Free Report) have earned an average rating of "Moderate Buy" from the fourteen brokerages that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and one has
Repligen Corporation (RGEN) Presents at Leerink Global Healthcare Conference 2026 Transcript
Repligen Corporation (RGEN) Presents at Leerink Global Healthcare Conference 2026 Transcript
